Hummingbird Diagnostics GmbH: Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research
Source: finanznachrichten.de